A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG
about
Neutrophils in the tumor microenvironment: trying to heal the wound that cannot heal.The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer.Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia.The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer.Trial-level analysis of progression-free survival and response rate as end points of trials of first-line chemotherapy in advanced ovarian cancer.Pretreated baseline neutrophil count and chemotherapy-induced neutropenia may be conveniently available as prognostic biomarkers in advanced gastric cancer.Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinum-based chemotherapy and prognosis in serous ovarian cancer.A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve.Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma.Short-course neoadjuvant chemoradiotherapy and surgery are beneficial in Chinese patients: A retrospective study.Does clinical trial participation improve outcomes in patients with ovarian cancer?
P2860
Q33816141-FB8AE19D-8D66-4BC2-9CD7-8E8E6774EE12Q36588945-B1263FEB-7096-48E8-A62D-F4BDD5A65E33Q37115871-B98AF3B4-351C-4528-8D73-D6DC13C24D45Q38750652-577EAD4A-423F-42CA-8F73-B8575E5E6FF6Q39229584-73F39B16-C802-4AFE-BA56-2C8FDEF1C5D7Q41076006-0D3E7F72-ED96-4CC1-8B2F-42D1B8FE469AQ44882899-F58846E3-6481-4341-91C6-476665E8A540Q47629735-2EEDC699-A455-472B-B0BF-143F078760A6Q48583884-9D5FC875-A685-4793-B8C8-7B7505677AC7Q49408362-BA72FAB6-1D56-4DA3-B12C-155E9C2A6A37Q54912094-04C18748-6E62-4946-B3C0-F6EF40FC06CB
P2860
A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
A multicenter, randomized tria ...... ANZGOG study on behalf of GCIG
@ast
A multicenter, randomized tria ...... ANZGOG study on behalf of GCIG
@en
type
label
A multicenter, randomized tria ...... ANZGOG study on behalf of GCIG
@ast
A multicenter, randomized tria ...... ANZGOG study on behalf of GCIG
@en
prefLabel
A multicenter, randomized tria ...... ANZGOG study on behalf of GCIG
@ast
A multicenter, randomized tria ...... ANZGOG study on behalf of GCIG
@en
P2093
P2860
P356
P1433
P1476
A multicenter, randomized tria ...... ANZGOG study on behalf of GCIG
@en
P2093
C Williams
P2860
P304
P356
10.1093/ANNONC/MDS494
P577
2012-10-05T00:00:00Z